pharmaphorum
JUNE 1, 2022
The technology behind virtual reality is rapidly advancing, allowing developers to create entire 3D hospitals for training purposes. In this article, Ben Hargreaves looks at how VR headsets are being used to better educate both healthcare professionals and the general public. Digital healthcare solutions are being talked about with increasing frequency.
Outsourcing Pharma
JUNE 1, 2022
Lithuaniaâs life sciences industry is growing at one of the fastest rates in Europe. Ahead of BIO, Innovation Agency Lithuania explains what the countryâs plans are for future growth in the area and how this is built upon students heading into STEM studies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Happy PharmD
JUNE 3, 2022
Evaluations— they were a necessary evil of my job. I didn’t like writing them, I didn’t like giving them. My staff didn’t like getting them. So why did I do them? Two reasons: 1) Management thought that employees liked or needed feedback about how well they were performing their job, and 2) evaluations were usually tied to some kind of merit increase.
Pharma Mirror
JUNE 2, 2022
SINGAPORE, Azelis, a leading innovation service provider in the specialty chemicals and food ingredients industry, announces the opening of its Regional Innovation Center (RIC) for Food & Nutrition (F&N) in Singapore, further demonstrating the Group’s commitment to continuously invest in its innovation capabilities. The RIC will generate a wealth of possibilities for food innovation towards healthier and tastier solutions through pioneering, ready-to-use formulations with advance
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MAY 31, 2022
Sanofi and Regeneron should hear from the FDA in the autumn whether it will approve their blockbuster immunology drug Dupixent as a therapy for rare skin disease prurigo nodularis (PN). The US regulator has granted Dupixent (dupilumab) a six-month priority review in PN and is due to deliver a verdict by 30 September, offering patients hope of a first-approved therapy for the highly-debilitating disease.
Outsourcing Pharma
MAY 31, 2022
Eli Lilly and Company plans to expand its manufacturing footprint in Indiana by investing $2.1bn in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Aureus Medical Group
MAY 31, 2022
Traveling is an exciting part of your job as a travel nurse; you get to see new parts of the country, experience new things, and make new connections! But there is a side-effect of constant travel– long-distance flights and changing time zones can impact your internal body clock, induce jet lag, or create confusion around time commitments. And after a long day of jumping through time zones, it can take up to one day for our body clocks to adjust for every hour the time shifts.
pharmaphorum
MAY 30, 2022
The American Society of Clinical Oncology, or ASCO, conference is just around the corner, but one subgroup of cancer researchers just had their own gathering, as breast cancer researchers came together in person for the first time since the start of the pandemic at the ESMO Breast Cancer congress. pharmaphorum sat down with Sunil Verma, global head of oncology, medical, at AstraZeneca, to discuss three studies that were presented at the show, which demonstrate a few of the ways oncology is advan
Outsourcing Pharma
JUNE 1, 2022
The Lifebit CloudOS will be employed to create a Federate Trusted Research Environment within the centerâs supercomputing cluster to handle data management.
Med Ed 101
JUNE 1, 2022
Though antipsychotics are generally used for long-term treatment of psychiatric conditions, there are several instances where therapy may be stopped altogether. We outline several practice pearls and clinical considerations when determining if antipsychotic tapering is appropriate. Deprescribing antipsychotic therapy may be appropriate in a number of different situations as listed below.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Colors Make me Happy
MAY 29, 2022
When I was the CEO for the SC Pharmacy Association, I would visit about 20 pharmacies a week. As I was waiting to meet with the team at each pharmacy, I watched each member of the community pharmacy team run from one end of the pharmacy to the next to answer the phones that did not stop ringing with calls from patients as well as providers, service the drive through customers, arrange for minute clinics as well as patient counseling, and take care of dozens of patients waiting in line for COVID-
pharmaphorum
MAY 30, 2022
In future, blood samples may be taken by an autonomous robot rather than a healthcare professional – if Dutch developer Vitestro can get its prototype approved for marketing. Vitestro’s blood drawing (phlebotomy) robot is designed to offer a solution to what the company says is a growing shortage of healthcare personnel, coupled with rising demand for blood tests with billions carried out every year worldwide.
Outsourcing Pharma
JUNE 1, 2022
A Touch, the Black Breast Cancer Alliance leader discusses how a grant from Genentech is helping the organization break down barriers in care and research.
Med Ed 101
MAY 29, 2022
ES is a 61-year-old female who is a resident in a long-term care facility. She has a history of drug abuse, early-onset dementia, GERD, chronic pain, and osteoarthritis. Her current medications include gabapentin 100 mg TID, donepezil 10 mg HS, omeprazole 20 mg in the morning, famotidine 20 mg in the evening, and acetaminophen 650 […]. The post Nitrofurantoin For Complicated UTI – Case Study appeared first on Med Ed 101.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Times
MAY 31, 2022
‘Act4Biosimilars’ will improve patient access and increase adoption in over 30 countries by 2030
pharmaphorum
JUNE 1, 2022
GlaxoSmithKline is due to complete the split from its consumer health decision – now renamed Haleon – next month, with a listing for the new company on the London Stock Exchange set for 18 July. GSK said it has now filed a prospectus for the submission of Haleon’s ordinary shares to the stock market with the Financial Conduct Authority (FCA), and is awaiting approval for the move.
Outsourcing Pharma
MAY 31, 2022
Withings Health Solutions' new remote patient monitoring (RPM) system seeks to tackle complexities identified after the launch of its first offering in the space.
The Honest Apothecary
JUNE 2, 2022
Respect /ri- spek /. “ To view or consider with some degree of reverence; to esteem as possessed of real worth. ” That’s how Noah Webster’s dictionary defined respect in 1828. But according to many workers, bosses today may need a reminder about the meaning of the word. For example, according to research by ISMP, disrespectful behavior within healthcare institutions is growing.
Pharma Times
MAY 30, 2022
The injection is given in combination with chemotherapy and administered once every three weeks
pharmaphorum
MAY 30, 2022
The World Health organisation’s latest assessment of the monkeypox outbreak is that it poses a moderate threat to public health, as cases of the infection continue to rise. In an update posted yesterday, the WHO said it had received reports of 257 confirmed cases of monkeypox from 23 countries, 106 of them from the UK and 49 from Portugal, with another 120 suspected cases being investigated.
Outsourcing Pharma
JUNE 2, 2022
This monthâs announcements of awards, investments, executive appointment, and expansions include Javara, Thread, uMotif, Lonza, and other notable companies.
pharmaphorum
MAY 30, 2022
GlaxoSmithKline is reportedly close to finding a development partner for a major new investment project in the UK that will see a new bioscience cluster built near its research centre in Stevenage. The pharma group said last year it was looking for a collaborator to develop a 33-acre block of land in the Hertfordshire town into a hub for life science companies, creating up to 5,000 jobs over the next decade.
pharmaphorum
JUNE 1, 2022
Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two glycoprotein targets. The Japanese drugmaker is paying $20.5 million upfront to get the ball rolling, while milestone and other payments could take the total value of the deal up to $783.5 million.
pharmaphorum
JUNE 1, 2022
Medical imaging specialist Median Technologies has launched a new business unit that will provide decision-making tools – underpinned by artificial intelligence – for sponsors of clinical trials in oncology. The new Imaging Lab business will deploy AI, data mining, and radiomics technologies to medical imaging data generated in cancer trials, said Median.
pharmaphorum
MAY 30, 2022
Josh Sackman, president and co-founder of AppliedVR, and Web Sun, president and co-founder of Komodo Health, relay how their newly formed collaboration reshapes the clinical trial process by using data, helping to cut costs and allowing for evaluation of broader patient populations. . AppliedVR and Komodo Health are collaborating to perform a clinical trial using the first FDA-authorised virtual reality (VR) platform and extensive data sets to look at the primary endpoints of chronic pain inten
pharmaphorum
MAY 31, 2022
The US Securities and Exchange Commission has sued a former AstraZeneca executive over alleged insider trading in connection with its 2019 deal to acquire rights to Daiichi Sankyo’s breast cancer therapy Enhertu. The complaint was filed against Hugues Pierre Joublin (54) – formerly global head of corporate affairs for oncology at AZ until his role was terminated on 15 December 2019 – in New York Southern District Court last week.
pharmaphorum
MAY 31, 2022
Pharma understands that building equitable health services starts with building equitable institutions. But how is the UK’s industry progressing on its equality, diversity, and inclusion pathway? And what more needs to be done? Equity, diversity, and inclusion (ED&I) strategies in the UK’s pharma sector are beginning to take shape, but there is still much work to be done.
pharmaphorum
MAY 30, 2022
Shares in Swedish biotech RhoVac were down 94% in mid-morning trading today after the company revealed a phase 2b trial of its prostate cancer vaccine RV001 showed it was no more effective than placebo. In the 180-subject BRaVac trial, treatment with RV001 (onilcamotide) was unable to top placebo in preventing disease progression among patients who had curative therapy for localised prostate cancer but subsequently saw a rise in levels of PSA, a biomarker for recurrence.
pharmaphorum
JUNE 1, 2022
For the first time since 2019, the American Society of Clinical Oncology (ASCO) annual meeting will be an in-person conference. We’re excited to re-connect with fellow oncology and clinical care professionals from across the globe to learn from one another and discuss key advances in cancer care and research. From innovations in cancer therapeutics to developments in genetic testing and biomarkers to the role of data analytics and technologies in oncology trials, insightful conversations can cre
pharmaphorum
JUNE 1, 2022
To improve outcomes for cancer patients and take advantage of the ground-breaking scientific and technological progress made in oncology prevention, diagnosis, therapy and care over recent years, it is of crucial importance to ensure all patients with cancer have an ongoing dialogue with the healthcare team. However, over the last years the COVID-19 pandemic has interrupted that dialogue in many places.
pharmaphorum
JUNE 1, 2022
Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just reported phase 2 trial results with the small, interfering RNA (siRNA) gene-silencing drug showing that it an cause a 90% or greater reduction in Lp(a) levels – a risk factor for cardiovascular disease – that was sustained over 48 weeks of follow-up.
pharmaphorum
MAY 30, 2022
It has been eight years since Sanofi licensed rights to an over-the-counter version of erectile dysfunction (ED) drug Cialis from Eli Lilly, and the FDA has just thrown a spanner into its plans to bring it to market in the US. Sanofi said this morning that the US regulator has imposed a clinical hold on its Actual Use Trial (AUT) of the OTC formulation over “matters surrounding the protocol design.” According to the French pharma group the study has not yet recruited any patients, an
pharmaphorum
MAY 29, 2022
The FDA has cleared two combination drug regimens based on Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for previously-untreated advanced oesophageal cancer, encroaching on territory held by Merck & Co’s rival Keytruda. The pair of new approvals are based on the results of the CheckMate-648 trial, and are for Opdivo (nivolumab) paired with chemotherapy or BMS’ CTLA4 inhibitor Yervoy (ipilimumab) as first-line therapy for advanced or metastatic oesophageal squamous cell carc
pharmaphorum
JUNE 2, 2022
R&D into orphan drugs is growing alongside the number of approved treatments, providing treatments for rare diseases that previously did not have any. However, Ben Hargreaves finds that the blockbuster success that certain treatments are achieving is beginning to raise questions over whether healthcare systems can afford this in the long-term. In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare dis
Expert insights. Personalized for you.
145 
Let's personalize your content